Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives

Roberto Baldelli, A. Barnabei, L. Rizza, A. M. Isidori, F. Rota, P. Di Giacinto, A. Paoloni, F. Torino, Salvatore Maria Corsello, A. Lenzi, M. Appetecchia

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare tumors that present many clinical features secreting peptides and neuroamines that cause distinct clinical syndromes such as carcinoid syndrome. However most of them are clinically silent until late presentation with mass effects. Surgical resection is the first line treatment for a patient with a GEP-NET while in metastatic disease multiple therapeutic approaches are possible. GEP-NETs are able to express somatostatin receptors (SSTRs) bounded by somatostatin (SST) or its synthetic analogs, although the subtypes and number of SSTRs expressed are very variable. In particular, SST analogs are used frequently to control hormone-related symptoms while their anti-neoplastic activity seems to result prevalently in tumor stabilization. Patients who fail to respond or cease to respond to standard SST analogs treatment seem to have a response to higher doses of these drugs. For this reason, the use of higher doses of SST analogs will probably improve the clinical management of these patients.
Original languageEnglish
Pages (from-to)7-7
Number of pages1
JournalFrontiers in Endocrinology
Volume5
DOIs
Publication statusPublished - 2014

Keywords

  • carcinoid
  • lanreotide
  • neuroendocrine tumors
  • octreotide
  • somatostatin analogs

Fingerprint

Dive into the research topics of 'Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives'. Together they form a unique fingerprint.

Cite this